CeriBell (NASDAQ:CBLL) Director Sells $338,792.78 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 16,714 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $20.27, for a total value of $338,792.78. Following the sale, the director directly owned 722,652 shares in the company, valued at $14,648,156.04. This trade represents a 2.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Josef Parvizi also recently made the following trade(s):

• On Thursday, January 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $22.94, for a total value of $573,500.00.
• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $21.49, for a total value of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Stock Performance

Shares of CeriBell stock opened at $18.95 on Thursday. The company has a market capitalization of $703.05 million, a PE ratio of -12.89 and a beta of 1.03. The company has a 50-day simple moving average of $21.20 and a two-hundred day simple moving average of $16.19. CeriBell, Inc. has a one year low of $10.01 and a one year high of $25.98. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 30.99%. The firm had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. Research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, Canaccord Genuity Group increased their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average target price of $24.67.

Hedge Funds Weigh In On CeriBell

Hedge funds and other institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its stake in CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CeriBell during the third quarter worth $33,000. CWM LLC lifted its position in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares during the period. Tower Research Capital LLC TRC boosted its holdings in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Finally, Ameritas Investment Partners Inc. grew its position in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 results beat expectations — CeriBell reported a narrower loss (‑$0.36 vs. consensus ‑$0.43) and revenue of $24.78M vs. estimates of $23.95M, signaling continued top‑line growth. CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
• Neutral Sentiment: FY‑2026 revenue guidance given at $111M–$115M (consensus ≈ $112.7M) while EPS guidance was not provided — revenue range is roughly in line but the lack of EPS guidance leaves forward profitability unclear. Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Full earnings call transcript and summaries are available for deeper color on growth drivers (market expansion, product adoption) and margin dynamics — useful for investors assessing cadence of revenue and path to profitability. CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Significant insider selling: CEO, CFO, CTO, CRO and a VP reported sales (small single‑day reductions each), and a director recently sold 16,714 shares — the cluster of disposals (filed with the SEC) can be interpreted as a negative signal and likely contributed to today’s heavier volume and price pressure. CeriBell (NASDAQ:CBLL) Insider Buying and Selling

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.